Research
Hormonal
Tirzepatide's effect is largely mediated by its GIP component.
Understanding that GIP mediates tirzepatide's effects can help practitioners optimize treatment strategies.
StrongSupportsmedium confidence
O efeito da tirzepatide é amplamente mediado pelo seu componente GIP.
Why this rating
The claim is based on a direct statement in the abstract about the mediation of tirzepatide's effects.
Source
Evidências cientificas sobre o uso de tirzepatida como tratamento da obesidade
Bernardo Carneiro de Sousa Guimarães et al. · Brazilian Journal of Health Review · 2022
DOI 10.34119/bjhrv5n4-137
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →